Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

Fig. 2

Progression-free survival in (a) all treated patients. (b) Patients with or without brain metastases at baseline. (c) Patients with uncommon EGFR mutations (excluding T790M or exon 20 insertions). (d) Patients aged < 65 or ≥ 65 years. (CI: confidence interval; PFS: progression-free survival)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us